When compared with histology, tumor size, and margin status, biological sub-types did not emerge as significant risk factors for LRR in a multivariate analysis of 1,994 patients (45% of luminal HER2 and 53% of HER2-positive received trastuzumab) (38). This evidence concerns the gene ERBB2 and neoplasm.